The primary aim of the study is to identify a predictive molecular signature for response to chemotherapy, according to WHO criteria, in patients with non-small cell lung cancer by studying the transcriptome (miRNAs and mRNAs) and the single nucleotide polymorphism (SNPs) by using high throughput techniques.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Enrollment
70
Standard cisplatin-based chemotherapy in agreement with the ELCWP guidelines (available on the website www.elcwp.org)
Department of Pneumology Clinique Saint-Luc
Bouge, Belgium
Department of Intensive Care Unit and Thoracic Oncology Institut Jules Bordet
Brussels, Belgium
Service de Pneumologie Hôpital Erasme
Brussels, Belgium
Department of Pneumology Hôpital Saint-Joseph
Gilly, Belgium
Response rate
Time frame: response will be assessed every 3 cycles of chemotherapy according to WHO criteria
Survival
Time frame: Survival will be dated from the date of treatment
Progression-free survival
Time frame: Period between the date of treatment and the date of first progression or death
Duration of response
Time frame: period between the day of treatment and the date of first progression in patients with an objective response
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Hôpital Ambroise Paré
Mons, Belgium
Department of Pneumology Centre Hospitalier de Mouscron
Mouscron, Belgium